

## **Guidelines in classification, diagnosis, and treatment of the photodermatoses**

### **7. Endogenous: The (cutaneous) porphyrias**

---

#### **1 - Definition**

The porphyrias are a group of infrequent metabolic diseases caused by partial deficiencies of the activity of 7 sequentially acting enzymes in the biosynthesis pathway of haem. They are inherited diseases with the exception of sporadic Porphyria cutanea tarda. (PCT Type I) the most frequent form of porphyria. PCT type is the result of inactivation of hepatic Uroporphyrinogen-decarboxylase (URO-D) enzyme.

#### **2 - Pathogenesis**

The result of these enzyme deficiencies or inactivation is the accumulation of intermediate metabolites in the pathway, the porphyrin precursors or porphyrins in tissues and their excess excretion in urine or stool.

The haem biosynthesis pathway includes 8 enzymes. Each enzyme deficiency correlates with one form of Porphyria except for the first one – (™ - amino levulinic acid synthase - ALA-S) causing X-linked sideroblastic anemia. The deficiency of second and third enzymes – ALA dehydratase and PBG deaminase – are related with two clinical pictures – ALA dehydrase porphyria (ADP) and Acute Intermittent Porphyria (AIP) – the acute porphyrias with neurovisceral manifestations and no photosensitivity. These two forms of porphyria are out of the scope of these guidelines. From the fourth enzyme onwards photosensitivity manifestations are the main manifestations of the so called cutaneous and mixed porphyrias – associated to neurovisceral symptoms - which include : Congenital erythropoietic porphyria (CEP), Porphyria Cutanea Tarda / Hepatoerythropoietic Porphyria (PCT / HEP), Variegate Porphyria (VP), Hereditary Coproporphyrin (HCP) and Erythropoietic Protoporphyrin ( EPP ). (Table1)

The presence of genetic defects does not correlate with clinical expression of the disease because the many different genetic mutations that can be found cause different levels of enzyme deficiency. On the other hand clinical expression depends on the action of secondary acquired and environmental factors. (Table2)

#### **Clinical features**

#### **Classification**

**Porphyrias are classified in different ways:**

1 – By location of the excess porphyrin production: **erythropoietic or hepatic**

2 – By clinical manifestations : **acute** (neurovisceral manifestations and no cutaneous photosensitivity ), **cutaneous** (photosensitivity ) or **mixed** (photosensitivity + neurovisceral manifestations )

Considering the scope of this guideline of photodermatoses the following clinical forms will be considered

1. - Erythropoietic porphyrias . Congenial erythropoietic porphyria (CEP) and Erythropoietic Protoporphyrin (EPP)
2. - Hepatic porphyrias : Porphyria cutanea tarda ( PCT type 1 sporadic, PCT type 2 familial) , Hepatoerythropoietic porphyria HEP, Variegate Porphyria (VP) and Hereditary Coproporphyrin (HCP)

### **Epidemiology – Incidence / Prevalence**

Porphyria appears in individuals in all human races. The prevalence has been evaluated in a variable percentage of 0.5 – 10 per 100.000 in different populations.

Clinical penetrance of genetic defects is very low so that about 80 % of individual carriers of mutations will never present biochemical alterations or develop clinical symptoms. Only irrelevant enzyme activity reduction may be present.

Nevertheless high prevalence gives the possibility of appearance homozygous inheritance of defects without consanguinity and the appearance of rare “dual” porphyria forms with inheritance of two different defects in the same individual.

### **Photoinduced cutaneous Clinical manifestations**

Specific clinical cutaneous photoinduced manifestations of the different forms are grouped in:

#### Chronic photosensitivity:

CEP

PCT / HEP

VP / HCP (mixed porphyrias)

### Acute photosensitivity

EPP

Chronic symptoms are manifested by skin fragility with erosions appearing with minimal trauma and bullous photo-induced lesions. These lesions evolve to scarring and slowly progressing sclerodermiform skin transformation with mutilating lesions specially on acral areas as fingers, nose and ears. Scalp alopecia may appear

Acute photosensitivity is manifested with erythema, oedema and petechiae associated to skin tingling, burning and pain. upon light exposures evolving to peculiar skin thickening characteristic in EPP.

Ocular lesions may be present (scleromalacia) or even oral mucosal lesions. In CEP teeth discolouration is a specific clinical sign – erythrodontia – which appears as bright red fluorescent under Wood's light illumination.

On the other hand in some cutaneous porphyrias one has to consider the association with exogenous factors or other disorders that may influence the clinical evolution of the disease. Specially in the most frequent form of cutaneous porphyria, sporadic acquired PCT type I, clinical manifestations are due to the action of drugs (e.g. oestrogens), chemical substances (Hexachlorobenzene), alcohol, iron overload, and viral infections (Hepatitis C HCV, or Human immunodeficiency virus, HIV).

An evident relationship has been established with the inheritance of Hemochromatosis genetic defects.

Hepatobiliary alterations may be frequently associated with PCT and EPP and patients PCT especially associated with HCV may be prone to develop hepatocarcinoma.

Also haematological disease can be associated together with hematological malignancies especially in late onset porphyria..

Treatment procedures as hemodialysis may initiate PCT manifestations.

Pregnancy may influence the evolution of PCT and EPP.

There have been a number of reports of coincidence of porphyria with Lupus erythematosus or Dermatomyositis in the same patient.

Pathogenesis of photoinduced lesions in porphyria is complex. Porphyrins are phototoxic reactive molecules. accumulation of uroporphyrin and protoporphyrin in tissues allows phototoxic reaction production upon light exposure. This phototoxicity is the basis of cutaneous lesions through the generation of oxygen reactive species, lipid peroxidation leads to lesions of membrane structures and degranulation of

mastocytes, liberation of inflammation mediators, complement activation and increased collagen synthesis.

## **Diagnostic procedures**

After a **clinical assessment** , this diagnosis should be confirmed by laboratory work-up.

Laboratory study should include **(1) Biochemical investigation (2) Enzyme activity determination** and **(3)Genetic studies** in order to trace family carriers of the defect, risk of those carriers of presenting disease and establishment of associated genetic defects and risk factors.

### **1 Biochemical studies**

Biochemical investigation includes the study of porphyrin (uroporphyrin, coproporphyrin and protoporphyrin) and porphyrin precursors (aminolevulinic acid, porphobilinogen ) in urine, faeces and blood -plasma and RBC (See Diagnostic algorithm (Fig 1). and plasma specific fluorescence. peaks demonstration ( PCT, VP ).

**2 Enzyme activity determination.** This determination is usually performed in erythrocytes or leucocytes.

### **3 Genetic studies**

The search for the mutation responsible is advisable specially in severe clinical forms (CEP , HEP) or mixed porphyrias (VP , HCP) to trace carriers for genetic counselling and prevention of acute manifestations. Prenatal diagnosis has already been performed in cases of CEP.

It is also advisable to look for associated gene mutations in

**PCT - Investigation of haemochromatosis (HEFE) Mutations**

EPP - Investigation of Single-Nucleotide Polymorphisms of IVS3-48C alleles.

## **Treatment**

Management of cutaneous lesions

1 Photoprotection (cutaneous and ocular) (For all cutaneous and mixed forms)

**High protection broad band Sunscreens ( up to 600 nm)**

Adequate clothing and exposure behaviour

Organic glasses mounted in spectacles with upper, lower and lateral protection

Window glass protection with filtering films (yellow acrylate)

Attention to operating theatres illumination.

2 Avoidance of skin trauma

Management of metabolic alterations

PCT

- Phlebotomy – 400-500 ml / every 14 days – 2 – 6 months to keep Hb levels between 100 –110 g/L. . Treatment of choice in patients with HEFE mutations. Not suitable for patients with tendency to anaemia or with cardio-vascular disease. Also not suitable for patients with cirrhosis due to the demand of augmented hepatic albumin synthesis. Not suitable for children in case of physical or emotional stress.

May be used during pregnancy. In this case iron supplementation should be avoided.

Monitoring includes determination of Hemoglobin concentration, Ferritin levels and serum iron binding capacity.

- Low-dose Chloroquine - 125 mg twice a week 6 – 12 months.

This approach is not advisable in case of HEFE mutations.

- Desferrioxamine -1,5 gr- 8-10 h. infusion – 5 days/week – weekly to halving the uroporphyrin excretion level, 2-3 weeks monthly to normalisation of uroporphyrin level, 1 week every 2-3 months as maintenance. Or 200mg/Kg in 500 ml saline once a week to halving uroporphyrin excretion and twice monthly up to normalisation and once every 2-3 months as maintenance.

- Other approaches - High-dose chloroquine (this could lead to liver failure in some patients) , IFN if associated to Hepatitis Virus C , HAART if associated to HIV infection, Alkalinisation, Vitamin E, Cimetidine(120).

In haemodialysis patients :

- Desferrioxamine 1,5 –4 g with haemodialysis
- Erythropoietin 20-50 U/Kg after haemodialysis or low-volume phlebotomies  
50-10 mL/once or twice weekly.
- Plasmapheresis
- Plasma exchange

HEP

No specific treatment available but treatment as in CEP may be indicated.

VP / HCP

No specific treatment available but Phlebotomy as in PCT regimen may be applied

EPP

Photosensitivity

- Oral Betacarotene - 30 – 90 mg / day Infants 120-180 mg / day adults to keep plasma levels at 6-8 mg/L

- Other approaches - Oral Cysteine, Vitamin C, Cimetidine, NBUVB Phototherapy (only NBUV is evidence based)

### **Liver protoporphyrin deposition and hepatic dysfunction**

- Cholestyramine, RBC transfusions, Exchange transfusions, Intravenous hematin, Iron supplementation.

CEP

- High level transfusions ( attention to iron overload)
- Oral activated charcoal – 60 gr three times daily
- Cholestyramine
- Hydroxyurea

- Splenectomy
- Hematin (late onset CEP) 3 mg./Kg. Daily for 4 consecutive days.

### Transplantation

Severe forms of CEP and EPP Bone-marrow transplantation or Bone-marrow + Hepatic Transplantation. Liver transplantation is successful in the liver failure which is rarely associated with EPP, symptoms of EPP slowly recur. Liver failure in VP may also be treated by transplantation.

### Other management recommendations

- Ocular protection in all forms is advisable
- Avoidance of triggering factors

Specially in the case of sporadic acquired PCT it is important to avoid triggering or aggravating factors as:

Drug, Alcohol, Hormones/ Oestrogens, Nutritional status - Starvation, Tobacco

Infections ( HVC, HIV ), Haemodialysis, Iron overload (HFE Mutations)

Chlorinated hydrocarbons

### Follow up

Patients with porphyria should remain under control life-long clinically and biochemically. Levels of porphyrin excess excretion should be controlled periodically. Clinical evolution of lesions should be surveyed. In patients with

### PCT

Serology for hepatitis virus – HVC / HIV – should be periodically checked. Abdominal ultrasound for early detection of hepatic cirrhosis development in HVC + patients for appearance of hepatocarcinoma.

### EPP

Hepatic function and porphyrin profile changes for early detection of liver failure should be performed .( Decline of fecal protoporphyrin excretion and increase in urine coproporphyrin I > III ratio).

Gallstones formation

CEP and HEP

Follow-up of haemolytic anaemia

## Tables

**Table 1**

### The Porphyrrias

| Porphyria                                   | Deficient enzyme – Heme biosynthesis | Porphyrin overproduction<br>Erythropoietic / Hepatic | Clinical manifestations                             | Inheritance         |
|---|--------------------------------------|--|---|---------------------|
|   | ALA-synthase                         |  |   |                     |
| ALA dehydratase deficiency prophyria (ADP)) | ALA-Dehydratase                      | Hepatic  | Acute neuro-visceral                                | Autosomal recessive |
| Acute intermittent Porphyria (AIP)          | PBG Deaminase                        | Hepatic  | symptoms  | Autosomal dominant  |
| Congenital erythropoietic poprphyria (CEP)  | UROgen III Cosynthetase              | Erythropoietic                                       | Cutaneous Chronic                                   | Autosomal recessive |
| Porphyria cutanea tarda (PCT)               | UROgen                               | Hepatic  | Photosensitivity                                    | Autosomal dominant  |
| Hepatoeritropoietic prophyria (HEP)         | Decarboxylase                        | Hepatic Erythropoietic                               |   | Autosomal recessive |
| Hereditary coproporphyria (HCP)             | COPROgen Oxidase                     | Hepatic  | Acute neuro-visceral                                | Autosomal dominant  |
| Variegate porphyria (VP)                    | PPgen Oxidase                        | Hepatic  | symptoms +<br>Cutaneous Chronic<br>Photosensitivity | Autosomal dominant  |
| Erythropoietic protoporphyria (EPP)         | Ferrochelataase                      | Erythropoietic                                       | Cutaneous Acute<br>Photosensitivity                 | Autosomal dominant  |



**Table 2****Cutaneous and mixed Porphyria – Genetic Background**

| <b>Porphyria</b>  | <b>Enzyme<br/>Ref. Nr.</b>  | <b>Cromosomal<br/>location</b> | <b>Structure</b>   |
|---|-----------------------------|--------------------------------|--|
| <b>Congenital erythropoietic porphyria (CEP)</b>                              | <b>URO-S<br/>EC4.2.1.75</b> | <b>10q25.3-q26.3</b>           | <b>10 exons<br/>Hsk, 1+2B-10<br/>Ery. 2A<sup>a</sup>+2B-10</b> |
| <b>Porphyria cutanea tarda (Pct)<br/>Hepatoerythropoietic porphyria (HEP)</b> | <b>URO-D<br/>EC4.1.1.37</b> | <b>1p34</b>                    | <b>10 exons</b>  |
| <b>Hereditary coproporphyria (HCP)</b>  | <b>CPOX<br/>EC1.3.3.3</b>   | <b>3q12</b>                    | <b>7 exons</b>   |
| <b>Variegate porphyria (VP)</b>   | <b>PPOX<br/>EC1.3.3.4</b>   | <b>1q22</b>                    | <b>13 exons</b>  |
| <b>Erythropoietic protoporphyria (EPP)</b>                                    | <b>FECH<br/>EC4.99.1.1</b>  | <b>18q21.3</b>                 | <b>11 exons</b>  |

**Evidence support of treatment options in Cutaneous porphyrias**

(The British Association of Dermatologists guidelines for the management of skin disease – C.E.M. Griffiths – Br J Dermatol 1999;141:396-397 )

| <b><u>Porphyria</u></b> | <b><u>Treatment options</u></b>       | <b><u>Level of recommendation</u></b><br><b><u>(Class)</u></b> | <b><u>Level of evidence</u></b> |
|-------------------------|---------------------------------------|--|---------------------------------|
| PCT                     | Phlebotomies                          | <b>A</b>   | <b>1<sup>+</sup></b>            |
|                         | Low-dose Chloroquine                  | <b>A</b>   | <b>1<sup>+</sup></b>            |
|                         | IFN(+Hepatitis C infection)           | <b>B</b>   | <b>2<sup>++</sup></b>           |
|                         | Deferoxamine(Hemodialysis)            | <b>B</b>   | <b>2<sup>++</sup></b>           |
|                         | Erythropoietin(Hemodialysis)          |  |                                 |
| HEP                     | Treatment may be considered as in CEP | <b>C</b>   | <b>2<sup>+</sup></b>            |

|        |                             |          |                      |
|--------|-----------------------------|----------|----------------------|
| VP/HCP | Phlebotomy as in PCT        | <b>C</b> | <b>3</b>             |
| EPP    | Iron supplementation        | <b>D</b> | <b>3</b>             |
|        | Oral Betacarotene           | <b>B</b> | <b>2<sup>+</sup></b> |
|        | Oral Cysteine               | <b>D</b> | <b>3</b>             |
|        | Vitamin C                   | <b>D</b> | <b>3</b>             |
|        | Cholestyramine              | <b>D</b> | <b>3</b>             |
|        | RBC transfusions            | <b>D</b> | <b>3</b>             |
|        | Hematin                     | <b>D</b> | <b>3</b>             |
|        | NBUVB phototherapy          | <b>D</b> | <b>3</b>             |
|        | Bone marrow transplantation | <b>D</b> | <b>3</b>             |
|        | Liver transplantation       | <b>D</b> | <b>3</b>             |
| CEP    | 1-Biochemical normalisation | <b>D</b> | <b>3</b>             |
|        | High Level transfusions     | <b>D</b> | <b>3</b>             |
|        | Oral activated charcoal     | <b>D</b> | <b>3</b>             |
|        | Cholestiramine              | <b>D</b> | <b>3</b>             |
|        | Hydroxyurea                 | <b>D</b> | <b>3</b>             |
|        | Splenectomy                 | <b>D</b> | <b>3</b>             |
|        | Bone marrow transplantation | <b>D</b> | <b>3</b>             |

### **References Guideline Photodermatosis – Porphyria**

**Total references reviewed 3412**

**Selection general references**

**(Cutaneous pophryria 1960 -2007 – 564 items reviewed)**

- Woods SM, Peters HA, Jonson SA. Chelation therapy in cutaneous porphyria. A review and report of a five-year recovery. Arch Dermatol 1961 Dec;84:920-7.

- Eales L, Dowdle EB, Saunders SJ, Sweeny GD. The diagnostic importance of fecal porphyrins in the differentiation of the porphyrias. II Values in the cutaneous porphyrias. *S Afr J Lab Clin Med* 1963 Sep;18:126-34.
- Sweeney GD, Saunders SJ, Dowdle EB, Eales L. Effects of Chloroquine on patients with cutaneous porphyria of the “symptomatic” type. *Br Med J* 1965 May 15;1(5445):1281-5.
- Donald GF, Hunter GA, Roman W, Taylor AE. Cutaneous porphyria. Favourable results in twelve cases treated by chelation. *Australas J Dermatol* 1965 Dec;8(2):97-115.
- Thivolet J, Bondet P, Perrot H, Moene Y. Treatment of late cutaneous porphyrias with iron chelating agents (EDTA, Desferal). *Bull Soc Fr Dermatol Syphiligr* 1967;74(3):388-91.
- Sauer GF, Funk DD. Iron overload in cutaneous porphyria. *Arch Intern Med* 1969 Aug;124(2):190-6.
- Donald GF, Hunter GA, Roman W, Taylor AE. Current concepts of cutaneous porphyria and its treatment with particular reference to the use of sodium calcium edetate. *Br J Dermatol* 1970 Jan;82(1):70-5.
- Walsh JR, Lobitz WC Jr, Mahler DJ, Kingery FA. Phlebotomy therapy in cutaneous porphyria. Effect on iron and trace metals. *Arch Dermatol* 1970 Feb;101(2):167-72.
- Hunter GA, Donald GF. The treatment of cutaneous porphyria with chloroquine or D-penicillamine. *Br J Dermatol* 1970 Dec;83(6):702-3.
- Ippen H. Beta-carotene used for protection against light in cutaneous porphyria tarda? *Hautarzt* 1972 Jan;23(1):47.
- Jaqueti G, Ledo A, Gonzalez P, Gallego J, Corripio F. Treatment of delayed cutaneous porphyria by means of metabolic alkalization. *Actas Dermosifiliogr* 1972 May-Jun; 63(5-6):191-8.
- Malina L, Chlumsky DL. Oestrogen-induced familial porphyria cutanea tarda. *Br J Dermatol* 1975 Jun;92(6):707-9.
- Allen BR, Parker S, Thompson GG, Moore MR, Darby FJ, Hunter JA. The effect of treatment on plasma uroporphyrin levels in cutaneous hepatic porphyria. *Br J Dermatol* 1975 Jul;93(1):37-42.
- Macdonald DM, Nicholson DC. Erythropoietic protoporphyria. Hepatic implications. *Br J Dermatol* 1976 Aug;95(2):157-62.
- Keczkes K, Barker DJ. Malignant hepatoma associated with acquired hepatic Cutaneous porphyria. *Arch Dermatol* 1978 Jan;112(1):78-82.
- Moshell AN, Bjornson L. Photoprotection in erythropoietic protoporphyria: Mechanism of photoprotection by beta-carotene. *J Invest Dermatol* 1977 Mar;68(3):157-60.
- Hunter GA, Donald GF. The treatment of cutaneous porphyria. *Australas J Dermatol* 1977 Apr;18(1):1-3.
- Briveet F, Drueke T, Guillemette J, Zingraff J, Crosnier J. Porphyria cutanea tarda – like syndrome in hemodialyzed patients. *Nephron* 1978;20(5):258-66.
- Ayres S Jr, Mihan R. Porphyria cutanea tarda: response to vitamin E. A review and two case reports. *Cutis* 1978 Jul;22(1):50-2.
- Herrero C, Muniesa A. Effect of chloroquine in porphyria cutanea tarda. *Med Cutan Ibero Lat Am* 1980;8(4-6):139-45.
- Malkinson FD, Levitt L. Hydroxychloroquine treatment of porphyria cutanea tarda. *Arch Dermatol* 1980 Oct;116(10):1147-50.

- Perrot H. Treatment of cutaneous porphyria. *Ann Dermatol Venereol* 1982;109(2):183-7.
- Disler P, Day R, Burman N, Blekkenhorst G, Eales L. Treatment of hemodialysis-related porphyria cutanea tarda with plasma exchange. *Am J Med* 1982 Jun;72(6):989-93.
- Brambilla L, Bellati G, Ideo G, Ronchi G, Finzi AF. Hydroxychloroquine with or without prednisone in the therapy of porphyria cutanea tarda and the associated hepatopathy. Preliminary results of a prospective trial. *G Ital Dermatol Venereol* 1983 Jul-Aug;118(4):261-6.
- Gibertini P, Rocchi E, Cassanelli M, Pietrangelo A, Ventura E. Advances in the treatment of porphyria cutanea tarda. Effectiveness of slow subcutaneous desferrioxamine infusion. *Liver* 1984 Aug;4(4):280-4.
- Marchesi L, Di Padova C, Cainelli T, Reseghetti A, Di Padova F, Rovagnati P, Cantoni L. A comparative trial of desferrioxamine and hydroxychloroquine for treatment of porphyria cutanea tarda in alcoholic patients. *Photodermatol* 1984 Dec;1(6):286-92.
- Salata H, Cortes JM, Enriquez de Salamanca R, Oliva H, Castro A, Kusak E, Carreno V, Hernandez Guio C. Porphyria cutanea tarda and hepatocellular carcinoma. Frequency of occurrence and related factors. *J Hepatol* 1985;1(5):477-87.
- Poh-Fitzpatrick MB. Porphyrin-sensitized cutaneous photosensitivity: pathogenesis and treatment. *Clin Dermatol* 1985 Apr-Jun;3(2):41-82.
- Poh-Fitzpatrick MB. The erythropoietic porphyrias. *Dermatol Clin* 1986 Apr;4(2):291-6. Grossman ME, Poh-Fitzpatrick MB. Porphyria cutanea tarda. Diagnosis, management, and differentiation from other hepatic porphyrias. *Dermatol Clin* 1986 Apr;4(2):297-309.
- Nonaka S, Ohgami T, Murayama F, Yamashita K, Yoshida H. Five cases of porphyria cutanea tarda with mild cutaneous changes: evaluation of the efficacy of phlebotomy by the pattern analysis of urinary porphyrins. *J Dermatol* 1986 Jun;13(3):196-202.
- Gordeuk VR, Brittenham GM, Hawkins CW, Mukhtar H, Bickers DR. Iron therapy for hepatic dysfunction in erythropoietic protoporphyria. *Ann Intern Med*. 1986 Jul;105(1):27-31.
- Tsega E. Long-term effect of high-dose, short-course chloroquine therapy on porphyria cutanea tarda. *Q J Med* 1987 Nov;65(247):953-7.
- Blauvelt A, Harris HR, Hogan DJ, Jimenez-Acosta F, Ponce I, Pardo RJ. Porphyria cutanea tarda and human immunodeficiency virus infection. *Int J Dermatol* 1992 Jul;31(7):474-9.
- Poh-Fitzpatrick MB, Honig PJ, Kim HC, Sassa S. Childhood-onset familial porphyria cutanea tarda: effects of therapeutic phlebotomy. *J Am Acad Dermatol* 1992 Nov;27(5 Pt 2):896-900.
- Fargion S, Piperro A, Cappellini MD, Sampietro M, Francanzani AL, Romano R, Caldarelli R, Marcelli R, Vecchi L, Fiorelli G. Hepatitis C virus and porphyria cutanea tarda: evidence of a strong association. *Hepatology* 1992 Dec;16(6):1322-6.
- GH Elder. Molecular genetics of disorders of the haem biosynthesis. *J Clin Pathol* 1993;46(11):977-81.
- Enriquez de Salamanca R, Sepulveda P, Moran MJ, Santos JL, Fontanellas A, Hernandez A. Clinical utility of fluorometric scanning of plasma porphyrins for the diagnosis and typing of porphyrias. *Clin Exp Dermatol* 1993 Mar;18(2):128-30.
- Freeseemann A, Frank M, Sieg I, Doss MO. Treatment of porphyria cutanea tarda by the effect of chloroquine on the liver. *Skin Pharmacol* 1995;8(3):156-61.

- Rich JD, Mylonakis E, Nossa R, Chapnick RM. Highly active antiretroviral therapy leading to resolution of porphyria cutanea tarda in a patient with AIDS and hepatitis C. *Dig Dis Sci* 1999 May;44(5):1034-7.
- Lim HW, Cohen JL. The cutaneous porphyrias. *Semin Cutan Med Surg* 1999 Dec;18(4):285-92.
- Thunell S, Harper P. Porphirins, porphyrin metabolism, porphyrias. III Diagnosis, care and monitoring in porphyria cutanea tarda- suggestions for a handling programme. *Scand J Clin Lab Invest* 2000 Nov;60(7):561-79.
- Thunell S, Harper P, Brun A. Porphirins, porphyrin metabolism, porphyrias. IV. Pathophysiology of erythropoietic protoporphyria - diagnosis, care and monitoring of the patient. *Scand J Clin Lab Invest* 2000 Nov;60(7):581-604.
- Lambrecht RW, Bonkovsky HL. Hemochromatosis and porphyria. *Semin Gastrointest Dis* 2002 Apr;13(2):109-19.
- Badminton MN, Elder GH. Management of acute and cutaneous porphyrias. *Int J Clin Pract* 2002 May;56(4):272-8.
- S E Foran, G Abel. Guide to Porphyrias. *Am J Clin Pathol* 2003;119 (Suppl. 1):S86-S93.
- Lecha M, Herrero C, Ozalla D. Diagnosis and treatment of the hepatic porphyrias. *Dermatol Ther* 2003;16(1):65-72.
- N Stojeba, C. Meyer, C Jeanpierre, F Perrot, C. Hirth, T. Pottecher, J C Deybach. Recovery from a variegated porphyria by a liver transplantation. *Liver Transpl* 2004;10(7):935-8.
- Mehrany K, Drage LA, Brandthagen DJ, Pittelkow MR. Association of porphyria cutanea tarda with hereditary hemochromatosis. *J Am Acad Dermatol* 2004 Aug;51(2):205-11.
- Lim HW. Pathogenesis of photosensitivity in the cutaneous porphyrias. *J Invest Dermatol* 2005 Jan;124(1):xvi-xvii.
- S Sassa. Modern diagnosis and management of the porphyrias. *Br J Haematol* 2006;135:281-292
- Poblete-Gutierrez P, Wiederholt T, Merk HF, Frank J. Laboratory tests and therapeutic strategies for the porphyrias. *Hautarzt* 2006 Nov;89(3):227-32.
- Taibjee SM, Stevenson OE, Abdullah A, Tan CY, Darbyshire P, Moss C, Goodyear H, Heagerty A, Whatley S, Badminton MN. Allogenic bone marrow transplantation in a 7-year-old girl with congenital erythropoietic porphyria: a treatment dilemma. *Br J Dermatol* 2007 Mar;156(3):567-71.

### **Other references**

#### **Dual porphyrias**

**(1960-2007 - 23 items reviewed)**

- Poblete-Gutierrez P, Badeloe S, Wiederholt T, Merk HF, Frank J. Dual porphyrias revisited. *Exp Dermatol*. 2006 Sep;15(9):685-91.

## **Congenital erythropoietic porphyria**

**(1960-2007 - 348 items reviewed)**

- Pimstone NR. Roles and pitfalls of transplantation in human porphyria. *Liver Transpl* . 2005 Dec;11(12):1460-2.
- Murphy GM. Diagnosis and management of the erythropoietic porphyrias. *Dermatol Ther* . 2003;16(1):57-64
- Dawe SA, Peters TJ, Du Vivier A, Creaner JD. Congenital erythropoietic porphyria: dilemmas in present day management. *Clin Exp Dermatol* . 2002 Nov;27(8):680-3
- Takamura N, Kurihara K, Yamashita S, Konndo M. Need for measurement of porphyrins in teardrops in patients with congenital erythropoietic porphyria. *Br J Ophthalmol* . 2002 Oct;86(10):1188.
- Desnik RJ, Astrin KH. Congenital erythropoietic porphyria: advances in pathogenesis and treatment. *Br J Haematol* . 2002 Jun;117(4):779-95.
- Chakrabarti A, Tan CY. Dietary fish oils as a therapeutic option in erythropoietic protoporphyria. *Clin Exp Dermatol* . 2002 Jun;27(4):324-7.
- Harada FA, Shwayder TA, Desnick RJ, Lim HW. Treatment of severe congenital erythropoietic porphyria by bone marrow transplantation. *J Am Acad Dermatol* . 2001 Aug;45(2):279-82.
- Shaw PH, Mancini AJ, McConnell JP, Brown D, Kletzel M. Treatment of congenital erythropoietic porphyria in children by allogeneic stem cell transplantation: a case report and review of the literature. *Bone Marrow Transplant* . 2001 Jan;27(1):101-5.
- Dahla-Dahmane F, Dommergues M, Narcy F, Gubler MC, Dumez Y, Gauthier E, Nordmann Y, Nessmann C, Terrasse G, Muller F. Congenital erythropoietic porphyria: prenatal diagnosis and autopsy findings in two sibling fetuses. *Pediatr Dev Pathol* . 2001 Mar-Apr;4(2):180-4.

- Ezcan I, Xu W, Gur gey A, Tuncer M, Ceitn M, Oner C, Yetgin S, Ersoy F, Aizencang G, Astrin KH, Desnick RJ. Congenital erythropoietic porphyria successfully treated by allogeneic bone marrow transplantation. *Blood* . 1998 Dec 1;92(11):4053-8.
- Murphy GM. Evaluation of porphyria. *Photodermatol Photoimmunol Photomed* . 1998 Apr;14(2):58-63.
- Mascaro JM. Management of the erythropoietic porphyrias. *Photodermatol Photoimmunol Photomed* . 1998 Apr;14(2):44-5.
- Minder EI, Schneider-Yin X, Moll F. Lack of effect of oral charcoal in congenital erythropoietic porphyria. *N Engl J Med* . 1994 Apr 14;330(15):1092-4.
- Guarini L, Piomelli S, Poh-Fitzpatrick MB. Hydroxyurea in congenital erythropoietic porphyria. *N Engl J Med* . 1994 Apr 14;330(15):1091-2.
- Roberts JE, Mathews-roth M. Cysteine ameliorates photosensitivity in erythropoietic protoporphyria. *Arch Dermatol* . 1993 Oct;129(10):1350-1.
- Hift RJ, Meissner PN, Kirsch RE. The effect of oral activated charcoal on the course of congenital erythropoietic porphyria. *Br J Dermatol* . 1993 Jul;129(1):14-7.
- Kauffman L, Evans DI, Steverns RF, Weinkove C. Bone-marrow transplantation for congenital erythropoietic porphyria. *Lancet* . 1991 Jun 22;337(8756):1510-1
- Rank JM, Straka JG, Weimer MK, Boaamaier I, Taddeni BL, Bloomer JR. Hematin therapy in late onset congenital erythropoietic porphyria. *Br J Haematol* . 1990 Aug;75(4):617-8
- Tishler PV. Oral charcoal therapy of congenital erythropoietic porphyria. *Hepatology* . 1988 Jan-Feb;8(1):183-4.
- Pimstone NR, Gandhi SN, Mukerji SK. Therapeutic efficacy of oral charcoal in congenital erythropoietic porphyria. *N Engl J Med* . 1987 Feb 12;316(7):390-3.
- Piomelli S, Poh-Fitzpatrick MB, Seaman C, Skolnick LM, Berdon WE. Complete suppression of the symptoms of congenital erythropoietic porphyria by long-term treatment with high-level transfusions. *N Engl J Med* . 1986 Apr 17;314(16):1029-31.
- Pimstone NR. Hematologic and hepatic manifestations of the cutaneous porphyrias. *Clin Dermatol* . 1985 Apr-Jun;3(2):83-102.
- Seip M, Thune PO, Eriksen L. Treatment of photosensitivity in congenital



erythropoietic porphyria (CEP) with beta-carotene. *Acta Derm Venereol* .

1974;54(3):239-40.

### **Erythropoietic protoporphyria**

**(1960-2007 - 664 items reviewed)**

- Holme SA, Thomas CL, Whatley SD, Bentley DP, Anstey AV, Badminton MN. Symptomatic response of erythropoietic protoporphyria to iron Hepatic complications of erythropoietic protoporphyria. supplementation. *J Am Acad Dermatol* . 2007 Jun;56(6):1070-2.
- Anstey AV, Hift RJ. Liver disease in erythropoietic protoporphyria: insights and implications for management. *Gut* . 2007 Jul;56(7):1009-18.
- Rand EB, Bunin N, Cochran W, Ruchelli E, Olthoff KM, Bloomer JR. Sequential liver and bone marrow transplantation for treatment of erythropoietic protoporphyria. *Pediatrics* . 2006 Dec;118(6):e1896-9.
- Madu AE, Whittaker SJ. Erythropoietic protoporphyria in pregnancy. *J Obstet Gynaecol* . 2006 Oct;26(7):687-8.
- Murphy GM, Hawk JL. Erythropoietic protoporphyria advances today, with a special tribute to the late Professor Ian Magnus. *Br J Dermatol* . 2006 Sep;155(3):501-3.
- McGuire BM, Bonkovsky HL, Carithers RL, Chung RT, Goldstein LI, Lake JR, Lok AS, Potter CJ, Rand E, Voigt MD, Davis PR, Bloomer JR. Liver transplantation for erythropoietic protoporphyria liver disease. *Liver Transpl* . 2005 Dec;11(12):1590-6.
- Todd DJ. Therapeutic options for erythropoietic protoporphyria. *Br J Dermatol* . 2000 Apr;142(4):826-7.

- Sassa S. Hematologic aspects of the porphyrias. *Int J Hematol* . 2000 Jan;71(1):1-17.
- N. Leone, A. Marzano, E Cerutti, G.C. Actis, P.E. Marchesa, E. David, -  
M.Salizzoni, M. Rizzetto. Liver transplantation for erythropoietic  
protoporphyrinemia: report of a case with medium-term follow-up. *Digest Liver Dis*.  
2000 ;32 :799-802
- Mathews-Roth MM. The treatment of erythropoietic protoporphyria. *Semin Liver  
Dis* . 1998;18(4):425-6.
- Warren LJ, George S. Erythropoietic protoporphyria treated with narrow-band (TL-  
01) UVB phototherapy. *Australas J Dermatol* . 1998 Aug;39(3):179-82.
- Gross U, Frank M, Doss MO. Hepatic complications of erythropoietic protoporphyria.  
*Photodermatol Photoimmunol Photomed* . 1998 Apr;14(2):52-7.
- Von Laar J, Stahl W, Bolsen K, Goerz G, Sies H. Beta-carotene serum levels in  
patients with erythropoietic protoporphyria on treatment with the synthetic all-trans  
isomer or a natural isomeric mixture of beta-carotene. *J Photochem Photobiol B* .  
1996 Apr;33(2):157-62.
- Sarkany RP, Cox TM. Liver failure in erythropoietic protoporphyria.  
*J Am Acad Dermatol* . 1996 Mar;34(3):540-1.
- Boffa MJ, Ead RD, Reed P, Weinkove C. A double-blind, placebo-controlled,  
crossover trial of oral vitamin C in erythropoietic protoporphyria.  
*Photodermatol Photoimmunol Photomed* . 1996 Feb;12(1):27-30.
- Norris PG, Baker Cs, Roberts JE, Hawk JL. Treatment of erythropoietic  
protoporphyrinemia with N-acetylcysteine. *Arch Dermatol* . 1995 Mar;131(3):354-5.
- Mathews-Roth MM, Rosner B, Benfell K, Roberts JE. A double-blind study of  
cysteine photoprotection in erythropoietic protoporphyria. *Photodermatol  
Photoimmunol Photomed* . 1994 Dec;10(6):244-8.

- Sarkany RP, Norris PG. Hepatic complications of erythropoietic protoporphyria. Br J Dermatol . 1994 Feb;130(2):258-9.
- Roberts JE, Mathews-Roth M. Cysteine ameliorates photosensitivity in erythropoietic protoporphyria. Arch Dermatol . 1993 Oct;129(10):1350-1.
- Yamamoto S, Hirano Y, Horie Y. Cimetidine reduces erythrocyte protoporphyrin in erythropoietic protoporphyria. Am J Gastroenterol . 1993 Sep;88(9):1465-6.
- ME Corbett, A. Herxheimer, IA Magnus [et.al](#) The longterm treatment with beta-carotene in erythropoietic protoporphyria: a controlled trial Br J Dermatol 1977;97:655-62
- Mathews-Roth MM, Pathak UA, Fitzpatrick TB, Harber LC, Kass EH. Beta-carotene as an oral photoprotective agent in erythropoietic protoporphyria. JAMA. 1974 May 20;228(8):1004-8. / N Engl J Med. 1970 May 28;282(22):1231-4

### **Porphyria cutanea tarda**

**(1960-2007 - 1813 items reviewed)**

- Epstein JH, Redeker AG. PORPHYRIA CUTANEA TARDA SYMPTOMATICA (PCT-S): A STUDY OF THE EFFECT OF PHLEBOTOMY THERAPY. Arch Dermatol. 1965 Sep;92:286-90.
- Thivolet J, Bondet P, Perrot, Moette Y. Treatment of porphyria cutanea tarda by iron chelators (EDTA, Desferral)] Lyon Med. 1967 Aug 6;218(32):225-30.
- Wiegand SE, Copeman PW, Perry HO. Metabolic alkalization in porphyria cutanea tarda. Arch Dermatol. 1969 Nov;100(5):544-9.
- Perry HO, Mullanax MG. Wiegand SE. Metabolic alkalization therapy in

porphyria cutanea tarda. Arch Dermatol. 1970 Oct;102(4):359-67.

- Hoo TT. Evaluation of therapy in acquired porphyria cutanea tarda. S Afr Med J. 1971 Sep 25;:197-9.
- Kordac V, Semradova M. Treatment of porphyria cutanea tarda with chloroquine.Br J Dermatol. 1974 Jan;90(1):95-100.
- Ippen H.Treatment of porphyria cutanea tarda by phlebotomy. Semin Hematol. 1977 Apr;14(2):253-9.
- Swanbeck G, Wennerstern G. Treatment of porphyria cutanea tarda with chloroquine and phlebotomy.Br J Dermatol. 1977 Jul;97(1):77-81.
- Ayres S Jr, Mihan R. Porphyria cutanea tarda: response to vitamin E. A review and two case reports.Cutis. 1978 Jul;22(1):50-2.
- Enriquez de Salamanca R, Catalan T, Cruces MJ, Pena ML, Olmos A, Jimenez J. Patterns of porphyrin excretion in porphyria cutanea tarda under venesection treatment.Int J Biochem. 1980;12(5-6):861-8.
- Raff M, Fomanek I. [Treatment of porphyria cutanea tarda with intermittent chloroquine]Hautarzt. 1980 Aug;31(8):437-40.
- Malina L, Chlumsky J. A comparative study of the results of phlebotomy therapy and low-dose chloroquine treatment in porphyria cutanea tarda. Acta Derm Venereol. 1981;61(4):346-50.
- Wennersten G, Ros AM. Chloroquine in treatment of porphyria cutanea tarda. Long-term efficacy of combined phlebotomy and high-dose chloroquine therapy. Acta Derm Venereol Suppl (Stockh). 1982;100:119-23.

- Cainelli T, Di Padova C, Marchesi L, Gori G, Rovagnati P, Podenzani SA, Bessone E, Cantoni L. Hydroxychloroquine versus phlebotomy in the treatment of porphyria cutanea tarda. *Br J Dermatol*. 1983 May;108(5):593-600.
- Miyauchi S, Shiraishi S, Miki EF. Small volume plasmapheresis in the management of porphyria cutanea tarda. *Arch Dermatol*. 1983 Sep;119(9):752-5.
- Giberti P, Rocchi E, Cassanelli M, Pietrangelo A, Veentura E. Advances in the treatment of porphyria cutanea tarda. Effectiveness of slow subcutaneous desferrioxamine infusion. *Liver*. 1984 Aug;4(4):280-4.
- Ashton RE, Hawk JL, Magnus IA. Low-dose oral chloroquine in the treatment of porphyria cutanea tarda. *Br J Dermatol*. 1984 Nov;111(5):609-13.
- Marchesi L, Di Padova C, Cainelli T, Resghetti A, Di Padova F, Rovagnati P, Cantoni L. A comparative trial of desferrioxamine and hydroxychloroquine for treatment of porphyria cutanea tarda in alcoholic patients. *Photodermatol*. 1984 Dec;1(6):286-92.
- Riccioni N, Donati G, Soldani S, Scatena P, Arcabasso GD. Treatment of hemodialysis-related porphyria cutanea tarda with small repeated phlebotomies. *Nephron*. 1987;46(2):125-7.
- Praga M, Enriquez de Salamanca R, Andres A, Nieto J, Oliet A, Perpina J, Morales JM. Treatment of hemodialysis-related porphyria cutanea tarda with deferoxamine. *N Engl J Med*. 1987 Feb 26;316(9):547-8.
- Lobato MN, Berger TG. Porphyria cutanea tarda associated with the acquired immunodeficiency syndrome. *Arch Dermatol*. 1988 Jul;124(7):1009-10.
- Anderson KE, Goeger DE, Carson KW, Lee SM, Stead RB. Erythropoietin for the treatment of porphyria cutanea tarda in a patient on long-term hemodialysis. *N Engl J Med*. 1990 Feb 1;322(5):315-7.

- E. Rocchi, M. Casanelli, A Broghi, F Paolillo , M. Pradeli, S. Pelizzardi, A Vezzosi, E Gallo, M Baccarani Contri, E Ventura. Liver Iron Overload and Desferrioxamine Treatment of Porphyria cutanea tarda. *Dermatologica* 1991;182:27-31
- Yagoob M, Smyth J, Almad R, McClelland P, Fahal I, Kumar KA, Yu R, Verbow J. Haemodialysis-related porphyria cutanea tarda and treatment by recombinant human erythropoietin. *Nephron*. 1992;60(4):428-31.
- Petersen CS, Thomsen K. High-dose hydroxychloroquine treatment of porphyria cutanea tarda. *J Am Acad Dermatol*. 1992 Apr;26(4):614-9.
- Stevens BR, Fleuscher AB Jr, Piering F, Crosby DL. Porphyria cutanea tarda in the setting of renal failure. Response to renal transplantation. *Arch Dermatol*. 1993 Mar;129(3):337-9.
- Drago F, Battifoglio ML, Gelati G, Rebora A. Very low-dose chloroquine treatment for porphyria cutanea tarda. *Acta Derm Venereol*. 1995 Jul;75(4):329-30.
- Horie Y, Tamaka K, Okano J, Ohgi N, Kawasaki H, Yamamoto S, Kondo M, Sassa S. Cimetidine in the treatment of porphyria cutanea tarda. *Intern Med*. 1996 Sep;35(9):717-9.
- Adjarov D, Naydenova E, Ivanov E, Ivanova A. Choice of therapy in porphyria cutanea tarda. *Clin Exp Dermatol*. 1996 Nov;21(6):461-2.
- Okano J, Horie Y, Kawasaki H, Kondo M. Interferon treatment of porphyria cutanea tarda associated with chronic hepatitis type C. *Hepatogastroenterology*. 1997 Mar-Apr;44(14):525-8.
- Poux JM, Demontis R, Cadramel JF, Ghazali A, Fievet P, Nordmann Y. Porphyria cutanea

tarda in a dialyzed patient with hepatitis C virus infection: dramatic efficacy of

small repeated phlebotomies. Am J Med. 1997 Aug;103(2):163-4.

- Harper P, Hybinette T, Thunell S. Large phlebotomy in variegate porphyria. J Intern Med. 1997 Sep;242(3):255-9.
- Herrero C, Lecha M. Management of patients with porphyria cutanea tarda. Photodermatol Photoimmunol Photomed. 1998 Apr;14(2):64-5.
- Chung TY, Brashear R, Lewis C. Porphyria cutanea tarda and hepatitis C virus: a case-control study and meta-analysis of the literature. J Am Acad Dermatol. 1999 Jul;41(1):31-6.
- Stolzel U, Kostler E, Schuppan D, Richter M, Wollina U, Doss MO, Wittekind C, Tannapfel A. Hemochromatosis (HFE) gene mutations and response to chloroquine in porphyria cutanea tarda. Arch Dermatol. 2003 Mar;139(3):309-13.
- Kostler E, Wollina U. Therapy of porphyria cutanea tarda. Expert Opin Pharmacother. 2005 Mar;6(3):377-83.

---

Website

European Porphyria Initiative ( EPI) <http://www.porphyrria-europe.com>

**M. Lecha. Dermatology Department. Hospital Clínic. University of Barcelona.**

**Porphyria Investigation Group A. Carrió, C. Herrero, M. Lecha, E. Margarit, A. Sánchez, A. Soler, J To-Figueras. Colaborador: C. Badenas. IDIBAPS - 5.110 Genètica**

**c/ Villarroel , 170 - 08024 - Barcelona – Spain**

**Te. + 34 932 275 692 Fax. + 34 932 275 438**

**[4908mlc@comb.es](mailto:4908mlc@comb.es) / [4908mlc@comb.cat](mailto:4908mlc@comb.cat)**

---

**Conflict of Interest disclosure: The author states no conflict of interest**